HCFA MEDICARE PRESCRIPTION DRUG BENEFIT MEETING: CLAIMS PROCESSING
HCFA MEDICARE PRESCRIPTION DRUG BENEFIT MEETING: CLAIMS PROCESSING and audit review protopics that will be addressed by the Health Care Financing Administration (HCFA) at a Nov. 21 open meeting. The HCFA session was originally scheduled to take place on Nov. 2. The date was rescheduled because of difficulties finding a location for the meeting. The intent of the meeting, according to HCFA, is "to inform interested parties on HCFA's current thinking on implementing the required point-of-sale claims processing system as well as audit and medical review programs." Additionally, "it is an effort to seek input and ideas from interested parties on these aspects of prescription drug benefit, and a "Clearing up of misinformation." HCFA Associate Administrator for Operations Louis Hays and Bureau of Program Operations Deputy Director Frank Derville will speak on behalf of HCFA. The meeting also allows time for a question and answer session, which will be headed by four HCFA representatives involved with the prescription drug benefit program: Procedures Director Carol Walton; Office of Program Administration Director Marilyn Koch; and Office of Financial Operations Director Charles Schreibeis. HCFA estimates that over 100 individuals are currently registered for the meeting, including representatives from the pharmaceutical industry and software firms. The meeting will begin at 9 a.m. at the Altmeyer building, 6401 Security Boulevard, Baltimore, Maryland. Persons interested in attending should contact Michelle Sanders, at HCFA, (301-996-5760), before Nov. 10.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth